![The evolving treatment landscape for children with sickle cell disease - The Lancet Child & Adolescent Health The evolving treatment landscape for children with sickle cell disease - The Lancet Child & Adolescent Health](https://www.thelancet.com/cms/attachment/96f2c482-874c-475a-8a66-9019e03aaa99/gr1_lrg.jpg)
The evolving treatment landscape for children with sickle cell disease - The Lancet Child & Adolescent Health
![Frontiers | Understanding blood development and leukemia using sequencing-based technologies and human cell systems Frontiers | Understanding blood development and leukemia using sequencing-based technologies and human cell systems](https://www.frontiersin.org/files/Articles/1266697/fmolb-10-1266697-HTML-r1/image_m/fmolb-10-1266697-g001.jpg)
Frontiers | Understanding blood development and leukemia using sequencing-based technologies and human cell systems
![Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease](https://article.imrpress.com/journal/FBE/14/3/10.31083/j.fbe1403018/1945-0508-14-3-018/fig1.jpg)
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease
![Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology](https://www.thelancet.com/cms/attachment/8ea69c89-10c4-44c8-81ad-abcf8b3d7df2/gr1_lrg.jpg)
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin | Haematologica
![New therapeutic targets in transfusion-dependent and -independent thalassemia. - Abstract - Europe PMC New therapeutic targets in transfusion-dependent and -independent thalassemia. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6142569/bin/bloodbook-2017-278-g001.jpg)
New therapeutic targets in transfusion-dependent and -independent thalassemia. - Abstract - Europe PMC
![PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting](https://i1.rgstatic.net/publication/362486907_Morbidity_and_mortality_of_sickle_cell_disease_patients_is_unaffected_by_splenectomy_evidence_from_3_decades_follow-up_in_a_high-income_setting/links/636a4b5f37878b3e87911fae/largepreview.png)
PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting
![IJMS | Free Full-Text | Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia IJMS | Free Full-Text | Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia](https://www.mdpi.com/ijms/ijms-18-02778/article_deploy/html/images/ijms-18-02778-g001.png)
IJMS | Free Full-Text | Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
![Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient | Scientific Reports Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-73991-4/MediaObjects/41598_2020_73991_Fig1_HTML.png)